<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent progresses have changed the paradigms for the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Careful patient screening and prognostic stratification using IPSS score is necessary before any treatment decision </plain></SENT>
<SENT sid="2" pm="."><plain>For lower-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> where <z:hpo ids='HP_0001903'>anemia</z:hpo> is the major problem, treatment with ESA should be considered first </plain></SENT>
<SENT sid="3" pm="."><plain>In patients who require red blood cells transfusions, <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> must be monitored carefully in order to consider iron chelation therapy </plain></SENT>
<SENT sid="4" pm="."><plain>A new drug such as lenalidomide which is active in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with del5q is currently under investigation in non-del5q <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>For patients with higher-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> transformation is the major issue </plain></SENT>
<SENT sid="6" pm="."><plain>Therefore aggressive treatment approaches such as allogeneic <z:chebi fb="15" ids="50443">HSC</z:chebi> transplant or intensive chemotherapy can be offered to selected subsets of patients </plain></SENT>
<SENT sid="7" pm="."><plain>However, for the vast majority, demethylating agents and namely <z:chebi fb="0" ids="2038">5-azacytidine</z:chebi> currently represent the standard of care </plain></SENT>
<SENT sid="8" pm="."><plain>Patient information and participation in clinical trails are important aspects of the current management of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>